Goldman Sachs
NKTR icon

Goldman Sachs’s Nektar Therapeutics NKTR Stock Holding History

Goldman Sachs’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,833
Closed -$372K – 6801
2021
Q4 		$372K Buy
1,833
+333
+22% +$72.2K ﹤0.01% 5556
2021
Q3 		$404K Sell
1,500
-500
-25% -$120K ﹤0.01% 5326
2021
Q2 		$515K Buy
+2,000
New +$554K ﹤0.01% 5196
2018
Q4 		– Sell
-1,580
Closed -$1.45M – 5525
2018
Q3 		$1.45M Buy
+1,580
New +$1.35M ﹤0.01% 3812
2018
Q1 		– Sell
-2,593
Closed -$2.32M – 6231
2017
Q4 		$2.32M Sell
2,593
-74
-3% -$43.8K ﹤0.01% 3661
2017
Q3 		$960K Hold
2,667
– – ﹤0.01% 4607
2017
Q2 		$782K Buy
+2,667
New +$771K ﹤0.01% 4691
2015
Q3 		– Sell
-2,320
Closed -$435K – 7425
2015
Q2 		$435K Sell
2,320
-4,793
-67% -$825K ﹤0.01% 5333
2015
Q1 		$1.17M Buy
+7,113
New +$1.46M ﹤0.01% 4306
2014
Q4 		– Sell
-22,320
Closed -$4.04M – 7250
2014
Q3 		$4.04M Buy
+22,320
New +$4.27M ﹤0.01% 3220
2014
Q1 		– Sell
-3,333
Closed -$568K – 6869
2013
Q4 		$568K Buy
+3,333
New +$538K ﹤0.01% 5206

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs's NKTR Position: Q1 2026 in Review

Goldman Sachs reduced its Nektar Therapeutics (NKTR) stake by 14% in Q1 2026, selling an estimated $1.19M and leaving 126,942 shares worth $9.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3143.

Goldman Sachs first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $160M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Goldman Sachs held 126,942 shares of Nektar Therapeutics worth $9.13M as of Q1 2026.
  • Goldman Sachs sold 20,851 Nektar Therapeutics shares in Q1 2026, an estimated $1.19M.
  • Nektar Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3143 holding.
  • Goldman Sachs first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Nektar Therapeutics position peaked at $160M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.